Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
ProKidney Corp. (PROK) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $1.74, with a market capitalisation of $378.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.30 to $3.48. This page covers its latest market performance, valuation, price trends and company information.
$378.16M | |
$1.76 | |
$14.19 | |
$0.46 | |
$1.74 | |
1.00 | |
1.27M | |
-- | |
$3.48 | |
$1.30 | |
-- | |
-- |
ProKidney Corp. (PROK) is trading at $1.74 in pre-market trading as of 2026-09-16 09:12:00, up 0.11% ($0.00) from the previous close of $1.74
Pre-market trading shows how investors are pricing PROK before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, ProKidney Corp. (PROK) moved from $2.01 to $1.74, representing a decline of 13.33% ($0.27).
The stock traded between $1.72 and $2.09 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.33 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 20.3%
PROK is currently trading at $1.74, placing it 20.3% of the way from its 52-week low of $1.30 to its 52-week high of $3.48. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 231 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of ProKidney Corp. (PROK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.